Abstract
Background: Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs.
Method: However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may provide an alternative to opioids for the treatment of pain. However, systemically administered conventional benzodiazepines fail to produce antihyperalgesic effects, likely due to their concurrent sedative properties. Results: Recent evidence suggests that by targeting specific benzodiazepine-sensitive GABAA receptor subtypes, the sedative properties of benzodiazepines can be circumvented and these compounds may be useful alternatives to opioids for the treatment of chronic pain. Conclusion: The present review provides an overview of the GABAA receptor subtypes involved in pain transmission as well as implications for the development of analgesic medications.Keywords: Antihyperalgesic, benzodiazepine, drug development, disorders, GABAA, pain.
CNS & Neurological Disorders - Drug Targets
Title:GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update
Volume: 16 Issue: 6
Author(s): Bradford D. Fischer*
Affiliation:
- Cooper Medical School of Rowan University, Camden, NJ,United States
Keywords: Antihyperalgesic, benzodiazepine, drug development, disorders, GABAA, pain.
Abstract: Background: Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs.
Method: However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may provide an alternative to opioids for the treatment of pain. However, systemically administered conventional benzodiazepines fail to produce antihyperalgesic effects, likely due to their concurrent sedative properties. Results: Recent evidence suggests that by targeting specific benzodiazepine-sensitive GABAA receptor subtypes, the sedative properties of benzodiazepines can be circumvented and these compounds may be useful alternatives to opioids for the treatment of chronic pain. Conclusion: The present review provides an overview of the GABAA receptor subtypes involved in pain transmission as well as implications for the development of analgesic medications.Export Options
About this article
Cite this article as:
Fischer D. Bradford*, GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update, CNS & Neurological Disorders - Drug Targets 2017; 16 (6) . https://dx.doi.org/10.2174/1871527316666170207155149
DOI https://dx.doi.org/10.2174/1871527316666170207155149 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis
Current Pharmaceutical Design Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection
Current Drug Targets Charcot Neuroarthropathy: From the Laboratory to the Bedside
Current Diabetes Reviews IL-1β and IL-1Ra Variant Profiles in Turkish Patients with Diabetic Peripheral Neuropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Overview of Dietary Supplements Use: A Narrative Review
Current Nutrition & Food Science Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design subject Index To Volume 1
Current Molecular Medicine Commentary Research Highlights (Purines, Pores and Pain: Is it in Our Genes?)
CNS & Neurological Disorders - Drug Targets Prevalence and Predictors of Diabetic Peripheral Neuropathy in Newly Diagnosed Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Involvement of Metabolites and Non-coding RNAs in Diseases
Current Pharmaceutical Biotechnology Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Autonomic Nervous System Dysfunction in Sjogrens Syndrome
Current Rheumatology Reviews Pharmacological Perspectives of Ayurvedic Herbs <i>viz. Alstonia scholaris</i> L., <i>Picrorhiza kurroa, Swertia chirata</i> and <i>Caesalpinia crista</i> Against COVID- 19: A Mini-Review
Mini-Reviews in Organic Chemistry Metabolic Effects of Metformin in Humans
Current Diabetes Reviews The Role of Berberine in the Multi-Target Treatment of Senile Dementia
Current Topics in Medicinal Chemistry Efficacy of HGF Gene Transfer for Various Nervous Injuries and Disorders
Central Nervous System Agents in Medicinal Chemistry Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design